There is no single “best” HRT for everyone. The right hormone replacement therapy depends on whether you still have your uterus, your personal risk factors, how you prefer to take it, and which symptoms bother you most. That said, the evidence does point to some clear advantages for certain formulations and delivery methods, and understanding those differences puts you in a much stronger position when talking to your prescriber.
Estrogen Only vs. Combined HRT
The first thing that determines your HRT type is whether you have a uterus. If you’ve had a hysterectomy, estrogen-only therapy is the standard choice. It carries fewer long-term risks than combined therapy and effectively treats hot flashes, night sweats, and other menopause symptoms on its own.
If you still have your uterus, you need a progestogen alongside estrogen. Without it, estrogen stimulates the uterine lining to grow unchecked, raising the risk of endometrial hyperplasia and uterine cancer. The progestogen counteracts that growth. This combination is sometimes called “combined HRT,” and it’s not optional for people with an intact uterus.
Patches and Gels vs. Pills
How you take estrogen matters just as much as which type you take. The two main routes are oral (pills) and transdermal (patches, gels, or sprays), and they behave quite differently in the body. When you swallow an estrogen pill, it passes through the liver before reaching your bloodstream. That liver processing triggers changes in clotting factors, triglycerides, and how your body handles insulin. Transdermal estrogen bypasses the liver almost entirely, entering the bloodstream directly through the skin at a lower effective dose.
The biggest clinical difference is blood clot risk. A systematic review and meta-analysis found that oral estrogen carries roughly 63% higher risk of a first venous blood clot compared to transdermal estrogen. Every identified study in a large systematic review was consistent: the transdermal route is safer for clotting. This is especially relevant if you have other clot risk factors like obesity, smoking history, or a family history of blood clots.
Transdermal estrogen also produces a more favorable metabolic profile. It tends to lower triglycerides rather than raise them, has no apparent negative effect on insulin sensitivity, and creates larger LDL cholesterol particles that are more resistant to oxidation. Oral estrogen, by contrast, can worsen insulin resistance and increase fat tissue. For women with metabolic concerns, prediabetes, or high triglycerides, transdermal delivery has clear advantages.
Both routes are equally effective at relieving hot flashes, protecting bone density, and managing other vasomotor symptoms. The symptom relief is comparable. The safety profile is where patches and gels pull ahead.
Body-Identical vs. Compounded Hormones
You’ll often see “bioidentical” hormones marketed as a safer or more natural alternative. The important distinction here is between FDA-approved body-identical hormones and custom-compounded products. FDA-approved versions (like estradiol patches and micronized progesterone) are chemically identical to the hormones your ovaries produced. They go through rigorous testing for safety, efficacy, purity, and consistent dosing.
Compounded hormones are mixed by specialty pharmacies to custom specifications. They are not FDA-approved and are not required to demonstrate safety or efficacy through clinical trials. They lack standardized quality controls for purity and potency, and they don’t come with package inserts outlining known risks. OB/GYNs are the least likely specialists to consider compounded hormones safer or more effective than their FDA-approved counterparts, and the evidence supports that skepticism. If you want hormones that match what your body naturally made, FDA-approved body-identical formulations accomplish that with far more quality assurance.
When to Start and How Long to Continue
Timing plays a major role in how favorable HRT’s risk-benefit profile is for you. The current consensus from the North American Menopause Society is that for women under 60, or within 10 years of their last period, with no contraindications, the benefits of HRT clearly outweigh the risks for treating bothersome symptoms and preventing bone loss.
Starting HRT more than 10 years after menopause or after age 60 shifts the balance. The absolute risks of heart disease, stroke, blood clots, and dementia increase in that window. This doesn’t mean HRT is never appropriate for older women, but the decision requires more careful weighing.
As for duration, HRT can continue as long as you have symptoms that warrant it. The old advice to stop after five years came from early interpretations of the Women’s Health Initiative study, but long-term follow-up data tells a more reassuring story. After 18 years of cumulative follow-up, women who took HRT had virtually identical all-cause mortality rates to women who took a placebo: 27.1% versus 27.6%. Cancer mortality was also statistically indistinguishable between groups. Longer use should be a shared decision with your prescriber, with periodic check-ins to see whether you still need it.
Testosterone for Low Libido
Some women on HRT find that estrogen and progesterone resolve most symptoms but do nothing for low sex drive. The only evidence-based reason to add testosterone to a woman’s HRT is a diagnosis of hypoactive sexual desire disorder, a persistent, distressing loss of sexual interest that isn’t explained by relationship problems, mental health conditions, or other medications. It should be diagnosed through a thorough assessment, not a blood test alone.
At doses that approximate what premenopausal ovaries naturally produce, testosterone therapy increases satisfying sexual events by roughly one additional episode per month compared to placebo. It also improves desire, arousal, orgasmic function, and reduces sexual distress. The global consensus position is that testosterone is not appropriate for general energy, mood, or anti-aging purposes in women. Its use is narrow but well-supported within that specific indication.
What “Best” Typically Looks Like
Pulling the evidence together, the combination that most often emerges as the favorable starting point for menopausal women with a uterus is a transdermal estradiol patch or gel paired with micronized progesterone. This setup uses body-identical hormones, avoids liver metabolism, carries the lowest clot risk, and has good metabolic effects. For women without a uterus, transdermal estradiol alone is typically the simplest, safest option.
Your prescriber may adjust the delivery method or formulation based on your symptoms, health history, and how you respond. Some women prefer the convenience of a pill and have no risk factors that make oral delivery concerning. Others need a specific progestogen to manage breakthrough bleeding. The “best” HRT is the one that controls your symptoms with the fewest side effects, and that often takes some fine-tuning in the first few months.